competenow, Author at BAKX Therapeutics

February 1, 2023
Silicon Review

BAKX Therapeutics — unlocking the full therapeutic power of the biological pathways that control cell life and death
read more
January 3, 2023
Life Science Leader

Why Founder CEOs Deliver In Bear Markets
read more
November 16, 2022
BusinessWire

BAKX Welcomes Dr. Marina Konopleva to Its Scientific Advisory Board
read more
August 16, 2022
ScienceDirect

Targeting protein conformations with small molecules to control protein complexes
read more
March 15, 2022
BioWorld

Activating activators is strategy against apoptosis defectors
read more
March 7, 2022
Nature Communications

Co-targeting of BAX and BCL-XL proteins broadly overcomes resistance to apoptosis in cancer
read more
November 18, 2021
News Daily

BAKX Therapeutics Raises $25M Series A Round
read more
November 18, 2021
BusinessWire

BAKX Raises $25 Million to Develop Therapeutics Targeting Pro-Apoptotic Proteins and Mitochondrial Apoptosis Pathway
read more
July 27, 2021
Yahoo!

Ipsen Beefs Up Pre-Clinical Oncology Pipeline With Over $850M Deal With BAKX Therapeutics
read more
July 27, 2021
BusinessWire

BAKX Therapeutics enters world-wide collaboration agreement with Ipsen for BKX-001
read more